Shots:

• The collaboration utilizes PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets & patient stratification biomarkers for CNS disorders to be developed by Ono
• The collaboration strengthens PrecisionLife’s precision medicine & drug discovery capabilities & provides rights to Ono to select targets with genetic validation, mechanistic hypotheses, preclinical validation, and patient stratification biomarkers to optimize the clinical development of the assets
• Ono also obtains the global rights to develop & commercialize a pharmaceutical product acting on the target. PrecisionLife has analyzed ~40 high-value disease indications & maintains a deep portfolio of insights and patented discoveries in its DiseaseBank repository

Ref: Ono | Image: Ono